Eril® ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症1

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-003676-31-FR
(EUCTR)
31/12/201925/04/2018Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALSInhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS Amyotrophic lateral sclerosis
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Eril®
INN or Proposed INN: FASUDIL HYDROCHLORIDE
Other descriptive name: FASUDIL HYDROCHLORIDE
Georg-August-Universität GöttingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 2France;Germany;Switzerland